GOVX Geovax Labs Dashboard

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.

Company profile

Ticker

GOVX, GOVXW

Exchange

NASDAQ

Website

www.geovax.com/

CEO

David Dodd

Incorporated

Delaware

Location

Georgia

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Viatris • Bristol-Myers Squibb • Warner Chilcott ...

Former names

DAUPHIN TECHNOLOGY INC

SEC CIK

0000832489

Corporate docs

Articles of Incorporation & Bylaws

IRS number

870455038

GOVX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Small-Cap Biotech Execs On Latest Advancements, Post-Pandemic Return To Fundamentals

13 May 21

At the Benzinga Global Small Cap Conference Thursday, Jason McCarthy, senior managing director at Maxim Group, hosted a panel discussion on how biotech companies are getting back to fundamentals following an extremely disruptive period during the COVID-19 pandemic.

Schedule For Benzinga's Global Small Cap Conference Thursday, May 13, 2021

13 May 21

Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda * the list below is limited to some of the publicly-traded companies that will be presenting

Earnings Scheduled For May 6, 2021

6 May 21

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.

52 Biggest Movers From Yesterday

4 May 21

12 Health Care Stocks Moving In Monday's After-Market Session

3 May 21

Press releases

Pro users get this 30m faster

GeoVax to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

10 Jun 21

Atlanta, GA, June 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers,

GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit

11 May 21

Atlanta, Georgia--(Newsfile Corp. - May 11, 2021) - GeoVax Labs, Inc. (NASDAQ:GOVX) today announced that David Dodd, Chairman & CEO will be attending the Q2 Virtual Investor Summit. Event Q2 Investor

GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update

6 May 21

Additional Capital Raised to Support Acceleration ofCoronavirus and Immuno-Oncology Programs ATLANTA, GA, May 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology

GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021

6 May 21

Thinking about buying stock in Affimed NV, Geovax Labs, TherapeuticsMD, Fortress Biotech, or Fubotv?

9 Apr 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

6 May 21

21 Jun 21

31 Dec 21

Financial summary

Financial statements Chart GOVX financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Geovax Labs earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	20.84M	20.84M	20.84M	20.84M	20.84M	20.84M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	521.36K	315.47K	540.34K	334.41K
Cash used (since last report)	n/a	n/a	1.41M	850.76K	1.46M	901.87K
Cash remaining	n/a	n/a	19.44M	19.99M	19.39M	19.94M
Runway (months of cash)	n/a	n/a	37.3	63.4	35.9	59.6

Beta Read what these cash burn values mean

Recent insider trades

GOVX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Sep 20	Randal D Chase	Common Stock	Buy	Aquire P	No	No	5	16,613	83.07K	16,613
29 Sep 20	Randal D Chase	Common Stock Purchase Warrant Common Stock	Buy	Aquire P	No	No	5	16,613	83.07K	16,613
29 Sep 20	Dean G Kollintzas	Common Stock	Buy	Aquire P	No	No	5	11,987	59.94K	11,987
29 Sep 20	Dean G Kollintzas	Common Stock Purchase Warrant Common Stock	Buy	Aquire P	No	No	5	11,987	59.94K	11,987
29 Sep 20	Spencer John N JR	Common Stock	Buy	Aquire P	No	No	5	21,024	105.12K	21,024
29 Sep 20	Spencer John N JR	Common Stock Purchase Warrant Common Stock	Buy	Aquire P	No	No	5	21,024	105.12K	21,024
29 Sep 20	Robert T Mcnally	Common Stock	Buy	Aquire P	No	No	5	53,925	269.63K	53,925
29 Sep 20	Robert T Mcnally	Common Stock Purchase Warrant Common Stock	Buy	Aquire P	No	No	5	53,925	269.63K	53,925
29 Sep 20	Mark Reynolds	Common Stock	Buy	Aquire P	No	No	5	60,184	300.92K	60,184
29 Sep 20	Mark Reynolds	Common Stock Purchase Warrant Common Stock	Buy	Aquire P	No	No	5	60,184	300.92K	60,184

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

GOVX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

10.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	12	2	+500.0%
Opened positions	11	1	+1000.0%
Closed positions	1	4	-75.0%
Increased positions	0	0
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	2.74M	1.79M	+53.6%
Total shares	650.09K	528.39K	+23.0%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Cavalry Fund I Management	219.34K	$1.01M	NEW
Bigger Capital Fund L P	151.12K	$511K	0.0%
Citadel Advisors	75.3K	$330K	NEW
VIRT Virtu Financial	60.49K	$265K	NEW
Vanguard	50.55K	$221K	NEW
Geode Capital Management	37.52K	$164K	NEW
Welch & Forbes	27.99K	$123K	NEW
WFC Wells Fargo & Co.	10.54K	$46K	NEW
Squarepoint Ops	10.53K	$46K	NEW
BAC Bank Of America	2.77K	$12K	NEW

Largest transactions	Shares	Bought/sold	Change
Sabby Management	0	-377.27K	EXIT
Cavalry Fund I Management	219.34K	+219.34K	NEW
Citadel Advisors	75.3K	+75.3K	NEW
VIRT Virtu Financial	60.49K	+60.49K	NEW
Vanguard	50.55K	+50.55K	NEW
Geode Capital Management	37.52K	+37.52K	NEW
Welch & Forbes	27.99K	+27.99K	NEW
WFC Wells Fargo & Co.	10.54K	+10.54K	NEW
Squarepoint Ops	10.53K	+10.53K	NEW
BAC Bank Of America	2.77K	+2.77K	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Bristol-Myers Squibb • Pfizer • Astrazeneca • Novavax • Advaxis • Sanofi • Lumos Pharma • Glaxosmithkline • Tonix Pharmaceuticals Holding • Chinook Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Australia, began, bought, checkpoint, clade, compelling, concept, constructed, currency, deal, Europe, expend, experimental, external, franchise, GOVX, IRS, Japan, light, move, objective, opportunity, recombinant, relevant, stimulating, subtype, Symbol, target, targeted, Title, variance, Western

Removed: account, advancing, applicable, authorized, cancellation, certificate, Commencing, connection, conserve, consisted, consummated, continuing, delayed, Designation, dilute, dividend, doubt, effected, entitled, equal, event, expertise, fiscal, history, holder, incorporation, increased, independent, investing, involving, joint, liquidation, lower, medical, November, order, payment, penalty, pertinent, potentially, predominantly, preference, receipt, reduced, reimburse, represent, requiring, secure, sell, split, stated, statement, summary, volume, voting

From filing 10-Q 2021 Q1